From The Motley Fool · Matthew Benjamin · · 30s
Eli Lilly's biggest shareholder selling $347m stock
Lilly Foundation's $347m stock sale won't hurt your investment.
In brief
Lilly Foundation's $347m stock sale won't hurt your investment. Lilly shareholders shouldn't sell after largest shareholder's annual charity payout. Originally reported by The Motley Fool.
Lilly Foundation's $347m stock sale
The largest shareholder of Eli Lilly is selling 300,000 shares worth $347 million.
Annual charity payout
The sale is a required annual charity payout from the tax-exempt Lilly Foundation, not bearish activity.
GLP-1 drug dominance
Lilly's Mounjaro and Zepbound are the world's best-selling drugs, dominating the $190 billion GLP-1 market.
The main idea
Lilly shareholders shouldn't sell after largest shareholder's annual charity payout.
